| Published Application/Species/Sample/Dilution | Reference |
|---|
- western blot; Human papillomavirus type 16; loading ...; fig 5
| Li L, Wang H, Zhou Z, Luo J, Wang X, Xiao X, et al. C3-Luc Cells Are an Excellent Model for Evaluation of Cellular Immunity following HPV16L1 Vaccination. PLoS ONE. 2016;11:e0149748 pubmed publisher |
- western blot; Human papillomavirus; 1:20,000; fig 2
| Lamprecht R, Kennedy P, Huddy S, Bethke S, Hendrikse M, Hitzeroth I, et al. Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells. Sci Rep. 2016;6:20431 pubmed publisher |
- western blot; human; 1:1000
| Warren C, Griffin L, Little A, Huang I, Farzan M, Pyeon D. The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus. PLoS ONE. 2014;9:e96579 pubmed publisher |
| Li M, Huang J, Zhu Y, Huang Z, Zhang G, Huang J. Anti-L1 antibody-bound HPV16 pseudovirus is degraded intracellularly via TRIM21/proteasomal pathway. Virol J. 2022;19:90 pubmed publisher |
| Mboumba Bouassa R, Pere H, Gubavu C, Prazuck T, Jenabian M, Veyer D, et al. Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination. PLoS ONE. 2020;15:e0233084 pubmed publisher |
| Schäfer G, Graham L, Lang D, Blumenthal M, Bergant MaruÅ¡iÄ M, Katz A. Vimentin Modulates Infectious Internalization of Human Papillomavirus 16 Pseudovirions. J Virol. 2017;91: pubmed publisher |
| Day P, Thompson C, Lowy D, Schiller J. Interferon Gamma Prevents Infectious Entry of Human Papillomavirus 16 via an L2-Dependent Mechanism. J Virol. 2017;91: pubmed publisher |
| Krishnappa P, Mohamad I, Lin Y, Barua A. Expression of P16 in high-risk human papillomavirus related lesions of the uterine cervix in a government hospital, Malaysia. Diagn Pathol. 2014;9:202 pubmed publisher |
| Huang H, Lambert P. Use of an in vivo animal model for assessing the role of integrin ?(6)?(4) and syndecan-1 in early steps in papillomavirus infection. Virology. 2012;433:395-400 pubmed publisher |
| Day P, Pang Y, Kines R, Thompson C, Lowy D, Schiller J. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol. 2012;19:1075-82 pubmed publisher |
| Millán A, Gomez Sebastian S, Núñez M, Veramendi J, Escribano J. Human papillomavirus-like particles vaccine efficiently produced in a non-fermentative system based on insect larva. Protein Expr Purif. 2010;74:1-8 pubmed publisher |
| Johnson K, Kines R, Roberts J, Lowy D, Schiller J, Day P. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol. 2009;83:2067-74 pubmed publisher |
| Fernández San Millán A, Ortigosa S, Hervas Stubbs S, Corral Martínez P, Segui Simarro J, Gaétan J, et al. Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol J. 2008;6:427-41 pubmed publisher |
| Day P, Gambhira R, Roden R, Lowy D, Schiller J. Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol. 2008;82:4638-46 pubmed publisher |
| Steele J, Mann C, Rookes S, Rollason T, Murphy D, Freeth M, et al. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br J Cancer. 2005;93:248-59 pubmed |
